NERV
Price
$1.63
Change
-$0.01 (-0.61%)
Updated
Jul 8 closing price
Capitalization
11.4M
34 days until earnings call
SYRE
Price
$15.61
Change
+$0.31 (+2.03%)
Updated
Jul 8 closing price
Capitalization
942.12M
22 days until earnings call
Interact to see
Advertisement

NERV vs SYRE

Header iconNERV vs SYRE Comparison
Open Charts NERV vs SYREBanner chart's image
Minerva Neurosciences
Price$1.63
Change-$0.01 (-0.61%)
Volume$5.82K
Capitalization11.4M
Spyre Therapeutics
Price$15.61
Change+$0.31 (+2.03%)
Volume$555.71K
Capitalization942.12M
NERV vs SYRE Comparison Chart in %
Loading...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NERV vs. SYRE commentary
Jul 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NERV is a Hold and SYRE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 09, 2025
Stock price -- (NERV: $1.63 vs. SYRE: $15.61)
Brand notoriety: NERV and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NERV: 61% vs. SYRE: 97%
Market capitalization -- NERV: $11.4M vs. SYRE: $942.12M
NERV [@Biotechnology] is valued at $11.4M. SYRE’s [@Biotechnology] market capitalization is $942.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $309.49B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NERV’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • NERV’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, NERV is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NERV’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).

  • NERV’s TA Score: 4 bullish, 5 bearish.
  • SYRE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than NERV.

Price Growth

NERV (@Biotechnology) experienced а -2.40% price change this week, while SYRE (@Biotechnology) price change was +0.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.39%. For the same industry, the average monthly price growth was +14.41%, and the average quarterly price growth was +12.94%.

Reported Earning Dates

NERV is expected to report earnings on Aug 12, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+9.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($942M) has a higher market cap than NERV($11.4M). NERV has higher P/E ratio than SYRE: NERV (1.99) vs SYRE (1.72). NERV YTD gains are higher at: -26.629 vs. SYRE (-32.947). NERV has higher annual earnings (EBITDA): 8.58M vs. SYRE (-214.36M). SYRE has more cash in the bank: 565M vs. NERV (17.3M). NERV (0) and SYRE (0) have identical debt. NERV (0) and SYRE (0) have equivalent revenues.
NERVSYRENERV / SYRE
Capitalization11.4M942M1%
EBITDA8.58M-214.36M-4%
Gain YTD-26.629-32.94781%
P/E Ratio1.991.72116%
Revenue00-
Total Cash17.3M565M3%
Total Debt00-
FUNDAMENTALS RATINGS
NERV vs SYRE: Fundamental Ratings
NERV
SYRE
OUTLOOK RATING
1..100
5955
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
6463
P/E GROWTH RATING
1..100
9983
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NERV's Valuation (40) in the Biotechnology industry is somewhat better than the same rating for SYRE (74) in the Pharmaceuticals Major industry. This means that NERV’s stock grew somewhat faster than SYRE’s over the last 12 months.

NERV's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that NERV’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as NERV (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to NERV’s over the last 12 months.

SYRE's Price Growth Rating (63) in the Pharmaceuticals Major industry is in the same range as NERV (64) in the Biotechnology industry. This means that SYRE’s stock grew similarly to NERV’s over the last 12 months.

SYRE's P/E Growth Rating (83) in the Pharmaceuticals Major industry is in the same range as NERV (99) in the Biotechnology industry. This means that SYRE’s stock grew similarly to NERV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NERVSYRE
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
N/A
Bullish Trend 6 days ago
85%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HSEIX12.17N/A
N/A
Hartford Small Cap Value I
VLSIX17.77N/A
N/A
Virtus KAR Long/Short Equity I
AIFFX15.66N/A
N/A
Aristotle International Equity I-2
MRGJX54.16-0.03
-0.06%
MFS Core Equity R4
GRMRX28.75-0.02
-0.07%
Nationwide S&P 500 Index R